Nudging Providers to Curtail Dangerous Opioid Prescribing: A Trial to Investigate Mechanisms
How to cite
Sacarny, Adam; Jacobson, Mireille; Powell, David. 2020. "Nudging Providers to Curtail Dangerous Opioid Prescribing: A Trial to Investigate Mechanisms." AEA RCT Registry. AEARCTR-0006602. https://doi.org/10.1257/rct.6602-1.3000000000000003
Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.
* Primary investigator
Abstract
Despite an enormous policy response, opioid prescribing remains well above historical levels and harms from opioids continue to mount. Nearly all states have Prescription Monitoring Programs (PMPs) to facilitate safer prescribing of opioids and other drugs, but research suggests these systems only deliver benefits when health care professionals are required to use them. Even with PMP mandates in place, providers may be unaware of the dangers of co-prescribing opioids with benzodiazepines or gabapentinoids, which include increased risk of overdose and death. Working with the Minnesota state government, we will mail letters to guideline-discordant opioid prescribers that either highlight an upcoming legally mandated requirement to check the PMP before prescribing an opioid, inform and educate providers about their patients filling concurrent prescriptions and the dangers of such co-prescribing, or both. Study participants will be randomized to receive no intervention or one of the three treatment letters. Using administrative data, we will track effects of the letters on not only prescribing but also PMP usage and queries. Findings form the multiplicity of treatment messages and outcomes will shed light on the mechanisms driving overprescribing. Results will inform future work by state and local policymakers to make opioid prescribing safer.
Intervention
Prescribers will be assigned at random to one of four arms:
1. PMP Use Mandate Letter: Prescribers are sent letters with reminders about the mandate to check the PMP when prescribing opioids.
2. Prescribing Information Letter: Prescribers are sent letters with information about their patients who received co-prescriptions. The letters will provide clinical background on the harms of co-prescribing and encourage prescribers to avoid co-prescribing in the future.
3. Prescribing Information + PMP Use Mandate Letter: Prescribers are sent letters combining the content in arms 1 and 2, reminding them about the PMP use mandate and providing information about their patients who received co-prescriptions.
4. Control (As Usual / No Letter): These prescribers are not sent letters, the as-usual case.
Experimental design
At the start of the study, we will conduct a review of PMP records to identify prescribers who wrote opioid-benzodiazepine and opioid-gabapentinoid co-prescriptions. Prescribers will be randomized at 1:1:1:1 ratio to one of three treatment arms or a control arm. Then prescribers in the treatment arms will be sent two letters, one month apart.
Design details
Cited by
No citation data available for this registration yet.